Historical source coverage

2023

101 selected records with a cited source date in 2023. This archive is selective and does not imply continuous monitoring or complete historical coverage.

Explore 2023 by record type

4 types

December 2023

6 records

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT03795701

PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

November 2023

16 records

Clinical trials · Octreotide

ClinicalTrials.gov record NCT02381249

PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

Clinical trials · Octreotide

ClinicalTrials.gov record NCT02385617

PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

Regulatory · Semaglutide

Federal Register notice 2023-25485

The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT00541047

PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

Literature metadata · Linaclotide

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States.

PubMed lists PMID 32863841 in Drugs in context as Journal Article, with publication-date metadata of 2020-08-12 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

Literature metadata · Afamelanotide

Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

PubMed lists PMID 28003770 in The application of clinical genetics as Review, Journal Article, with publication-date metadata of 2016-12-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

October 2023

8 records

Literature metadata · GHK-Cu

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

PubMed lists PMID 37896245 in Pharmaceutics as Journal Article, with publication-date metadata of 2023-10-18 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

Clinical trials · Pramlintide

ClinicalTrials.gov record NCT05199714

PeptideScanner retained ClinicalTrials.gov record NCT05199714 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-25, and PeptideScanner's reviewed identity mapping was pramlintide.

Source: ClinicalTrials.gov ↗

September 2023

7 records

Literature metadata · Linaclotide

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation.

PubMed lists PMID 30302125 in Therapeutic advances in gastroenterology as Journal Article, with publication-date metadata of 2018-10-03 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

Clinical trials · Afamelanotide

ClinicalTrials.gov record NCT04525157

PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide.

Source: ClinicalTrials.gov ↗

Clinical trials · Setmelanotide

ClinicalTrials.gov record NCT02896192

PeptideScanner retained ClinicalTrials.gov record NCT02896192 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was setmelanotide.

Source: ClinicalTrials.gov ↗

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT04263415

PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT03737240

PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

Literature metadata · Linaclotide

Linaclotide (Linzess) for functional constipation.

PubMed lists PMID 37651297 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

August 2023

7 records

Regulatory · Exenatide

Federal Register notice 2023-18241

The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

Regulatory · Exenatide

Federal Register notice 2023-18250

The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

Regulatory · Glucagon + 1 more

Federal Register notice 2023-18026

The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.

Source: Federal Register via GovInfo ↗

Literature metadata · Elamipretide

Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

PubMed lists PMID 36636586 in JIMD reports as Journal Article, with publication-date metadata of 2022-09-21 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT04026256

PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

July 2023

7 records

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT04879420

PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

June 2023

10 records

Literature metadata · MOTS-c

Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.

PubMed lists PMID 36824008 in Diabetes & metabolism journal as Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-24 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

May 2023

11 records

Clinical trials · Setmelanotide

ClinicalTrials.gov record NCT03287960

PeptideScanner retained ClinicalTrials.gov record NCT03287960 at 2026-07-30T19:13:03.752Z. Its registry update date was 2023-05-23, and PeptideScanner's reviewed identity mapping was setmelanotide.

Source: ClinicalTrials.gov ↗

Literature metadata · Lixisenatide

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice…

PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

April 2023

4 records

Clinical trials · Afamelanotide

ClinicalTrials.gov record NCT04962503

PeptideScanner retained ClinicalTrials.gov record NCT04962503 at 2026-07-30T19:14:02.188Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was afamelanotide.

Source: ClinicalTrials.gov ↗

Clinical trials · Abaloparatide

ClinicalTrials.gov record NCT03512262

PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide.

Source: ClinicalTrials.gov ↗

March 2023

8 records

February 2023

10 records

Literature metadata · MOTS-c

Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study.

PubMed lists PMID 36844198 in Frontiers in medicine as Journal Article, with publication-date metadata of 2023-02-08 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

Regulatory · Afamelanotide + 3 more

Federal Register notice 2023-03364

The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.

Source: Federal Register via GovInfo ↗

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT03043807

PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

Clinical trials · Abaloparatide

ClinicalTrials.gov record NCT04064411

PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide.

Source: ClinicalTrials.gov ↗

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT04589819

PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

Clinical trials · Afamelanotide

ClinicalTrials.gov record NCT05368857

PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide.

Source: ClinicalTrials.gov ↗

Literature metadata · Pramlintide

Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles.

PubMed lists PMID 36704426 in Research in pharmaceutical sciences as Journal Article, with publication-date metadata of 2022-10-29 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

January 2023

7 records

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT03472846

PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

Clinical trials · Abaloparatide

ClinicalTrials.gov record NCT03746041

PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide.

Source: ClinicalTrials.gov ↗

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT02967757

PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

Literature metadata · Bremelanotide

An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.

PubMed lists PMID 36242769 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2022-10-18 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT02440581

PeptideScanner retained ClinicalTrials.gov record NCT02440581 at 2026-07-30T19:17:35.692Z. Its registry update date was 2023-01-05, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗